• Flanders crowns 3 foreign investors

    Wednesday March 23rd 2022

  • argenx announces positive topline Phase 3 data from ADAPT-SC study evaluating subcutaneous efgartigimod for generalized myasthenia gravis

    Tuesday March 22nd 2022

  • V-Bio Ventures’ Portfolio Company Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals

    Wednesday March 16th 2022

  • Confo Therapeutics doses first subjects in Phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain

    Thursday March 10th 2022

  • flanders.healthTech launches 14 unique innovation projects in healthcare

    Thursday March 10th 2022

  • MyCellHub strengthens its growth ambitions by appointing Jacques Parlongue as CEO

    Tuesday March 8th 2022

  • KU Leuven’s Biosensors group develops first label-free assay characterizing COVID-19 antibodies directly in patient blood, using FOx BIOSYSTEMS platform

    Tuesday March 8th 2022

  • UCB expands innovation footprint with new state-of-the-art gene therapy facility

    Tuesday March 8th 2022

  • Your news here?

  • Unexpected element in aging process discovered

    Friday March 4th 2022

  • V-Bio Ventures’ portfolio company Syndesi Therapeutics acquired by AbbVie to strengthen its neuroscience portfolio

    Wednesday March 2nd 2022

  • The fight against cancer intensified thanks to SCK CEN and the IRE

    Monday February 28th 2022

Strategic Partners